A Phase I, Open Label, Parallel Group, Single and Multiple Dose Study in Taiwanese Subjects Identified as CYP2C19 Poor Metabolizers or Extensive Metabolizers Receiving 20 Milligrams of Rosuvastatin Calcium.
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2015
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Hyperlipidaemia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors AstraZeneca
- 27 Feb 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 27 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Oct 2008 New trial record.